Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAPK1 | P53355 | 5/20 | 0.45 |
| ▸ | CSF1R | P07333 | 6/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807625 | 1.00 | DAPK1 (0.45) | DAPK1CSF1RLCKCCR3BTK | |
| SCHEMBL1807304 | 0.90 | MAPT (0.50) | DAPK1CSF1RLCKEGFRITK | |
| SCHEMBL1807303 | 0.90 | MAPT (0.50) | DAPK1CSF1RLCKEGFRITK | |
| SCHEMBL1806037 | 0.88 | PRMT5 (0.40) | CCR3 | |
| SCHEMBL1806036 | 0.88 | PRMT5 (0.40) | CCR3 | |
| SCHEMBL1805031 | 0.83 | PRMT5 (0.44) | MAPT | |
| SCHEMBL1808725 | 0.83 | PRMT5 (0.44) | MAPT | |
| SCHEMBL1805033 | 0.83 | PRMT5 (0.44) | MAPT | |
| SCHEMBL1808726 | 0.83 | PRMT5 (0.44) | MAPT | |
| SCHEMBL12653244 | 0.81 | PRMT5 (0.48) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493863-B1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-25 | — | — | EP | disclosed |
| EP-2493863-B1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-25 | — | — | EP | disclosed |
| US-8895573-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-8895573-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-8895573-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-8394809-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394809-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394809-B2 | Phenoxy-substituted pyrimidines as opioid receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-2493863-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2011-05-05 | — | — | US | disclosed |
| WO-2011053701-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053701-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066422-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | OPRK1, OPRL1, OPRM1 | DAPK1 2930/4885CSF1R 495/4885LCK 555/4885 |
| US-20110105455-A1 | PHENOXY-SUBSTITUTED PYRIMIDINES AS OPIOID RECEPTOR MODULATORS | OPRK1, OPRL1, OPRM1 | DAPK1 2930/4885CSF1R 495/4885LCK 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.